FROM PUBLIC EVENTS · 2026-11-15

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Global approvals · expansion Approved for its point-of-care platform under a Canadian partner's brand, it is starting overseas supply.

  • Health Canada approval of its quantitative point-of-care immunoassay platform. Source

Roles often seen at this stageRegulatory affairs · Sales & marketing · Device R&D & support

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-15

Sugentech

An in-vitro diagnostics company making a point-of-care immunoassay platform and allergy tests, widening sales with overseas partners.

INCLIX F-100

Approved

Quantitative point-of-care immunoassay platform approved as a Class II device by Health Canada.

SGTi-Allergy PLUS 120

Approved

Allergy test approved in Korea and seeking European certification.

Completion reported

Its point-of-care platform was approved by Health Canada.

Official role guide

Sugentech careers

Current availability unconfirmed

Observed 2026-11-15

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 수젠텍, 현장진단 플랫폼 캐나다 보건부 승인…글로벌 사업 확장한다 ↗한국경제 · Published 2026-08-07 · Sources checked 2026-11-15 · Original unavailable
  2. 수젠텍, 알레르기 검사 239종으로 확대…유럽 진출 준비 ↗브릿지경제 · Published 2026-10-29 · Sources checked 2026-11-15 · Original unavailable